Thelansis

Interstitial Lung Disease (ILD) Market Outlook Thelansis’s “Interstitial Lung Disease (ILD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Interstitial Lung Disease (ILD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Interstitial Lung Disease (ILD) Market Outlook Thelansis’s “Interstitial Lung Disease (ILD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Interstitial Lung Disease (ILD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Interstitial Lung Disease (ILD) Overview Interstitial lung disease (ILD) is a prevalent complication associated with connective tissue diseases (CTDs). While ILD can manifest across all CTDs, it is most frequently observed in conditions such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and idiopathic inflammatory myopathy (IIM). The potential risk factors vary depending on the underlying CTD. In the c...

  Interstitial lung disease (ILD) is a prevalent complication associated with connective tissue diseases (CTDs). While ILD can manifest across all CTDs, it is most frequently observed in conditions such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and idiopathic inflammatory myopathy (IIM). The potential risk factors vary depending on the underlying CTD. In the case of RA-associated ILD, advanced age, smoking, male gender, and the severity of RA disease score are strongly implicated. Diagnosis typically involves Pulmonary Function Tests (PFTs) and High-Resolution Computed Tomography (HRCT). For the management of systemic sclerosis-associated ILD, traditional immunosuppressive therapies such as mycophenolate mofetil (MMF) or cyclophosphamide (CYC) have been employed as initial treatments. Oxygen therapy should be administered based on assessments of resting, exercise, and nocturnal saturations to ensure patients maintain oxygen saturation above 88%. ...